156 related articles for article (PubMed ID: 9410328)
1. [Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990].
Grosclaude P; Menegoz F; Schaffer P; Macé Lesec'h J; Arveux P; Le Mab G; Soulié M; Villers A
Prog Urol; 1997 Sep; 7(4):647-54. PubMed ID: 9410328
[TBL] [Abstract][Full Text] [Related]
2. [Epidemiology of prostate cancer in the Limousin area].
Druet-Cabanac M; Colombeau P; Preux PM; Paulhac P; Vergnenegre A; Dumas JP
Prog Urol; 2002 Apr; 12(2):226-31. PubMed ID: 12108336
[TBL] [Abstract][Full Text] [Related]
3. Cancer incidence and mortality in France over the period 1978-2000.
Remontet L; Estève J; Bouvier AM; Grosclaude P; Launoy G; Menegoz F; Exbrayat C; Tretare B; Carli PM; Guizard AV; Troussard X; Bercelli P; Colonna M; Halna JM; Hedelin G; Macé-Lesec'h J; Peng J; Buemi A; Velten M; Jougla E; Arveux P; Le Bodic L; Michel E; Sauvage M; Schvartz C; Faivre J
Rev Epidemiol Sante Publique; 2003 Feb; 51(1 Pt 1):3-30. PubMed ID: 12684578
[TBL] [Abstract][Full Text] [Related]
4. [Incidence and mortality of prostate cancer in France: trends between 1978 and 2000].
Bauvin E; Remontet L; Grosclaude P; ;
Prog Urol; 2003 Dec; 13(6):1334-9. PubMed ID: 15000309
[TBL] [Abstract][Full Text] [Related]
5. [The epidemiology of prostate cancer].
Rébillard X; Tretarre B; Villers A
Rev Prat; 2003 Dec; 53(20):2224-8. PubMed ID: 15018075
[TBL] [Abstract][Full Text] [Related]
6. Trends in incidence of digestive cancers in France.
Lepage C; Remontet L; Launoy G; Trétarre B; Grosclaude P; Colonna M; Velten M; Buemi A; Danzon A; Molinie F; Maarouf N; Bossard N; Bouvier AM; Faivre J;
Eur J Cancer Prev; 2008 Feb; 17(1):13-7. PubMed ID: 18090905
[TBL] [Abstract][Full Text] [Related]
7. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
8. [Epidemiological trends in prostate cancer over the last years].
Luján Galán M; Páez Borda A; Chiva Robles V; Santonja Garriga C; Romero Cajigal I; Berenguer Sánchez A
Arch Esp Urol; 2004 Oct; 57(8):817-25. PubMed ID: 15560270
[TBL] [Abstract][Full Text] [Related]
9. [Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004].
Flamand V; Zini L; Salleron J; Fantoni JC; Biserte J; Villers A
Prog Urol; 2008 Jan; 18(1):53-9. PubMed ID: 18342157
[TBL] [Abstract][Full Text] [Related]
10. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
[TBL] [Abstract][Full Text] [Related]
11. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012.
Colonna M; Danzon A; Delafosse P; Mitton N; Bara S; Bouvier AM; Ganry O; Guizard AV; Launoy G; Molinie F; Sauleau EA; Schvartz C; Velten M; Grosclaude P; Tretarre B
Eur J Cancer; 2008 Jan; 44(1):115-22. PubMed ID: 18032021
[TBL] [Abstract][Full Text] [Related]
12. The effect of revised populations on mortality statistics for the United States, 2000.
Anderson RN; Arias E
Natl Vital Stat Rep; 2003 Jun; 51(9):1-24. PubMed ID: 12795490
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups.
Sandblom G; Holmberg L; Damber JE; Hugosson J; Johansson JE; Lundgren R; Mattsson E; Nilsson J; Varenhorst E
Scand J Urol Nephrol; 2002; 36(2):106-12. PubMed ID: 12028683
[TBL] [Abstract][Full Text] [Related]
14. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.
Edwards BK; Brown ML; Wingo PA; Howe HL; Ward E; Ries LA; Schrag D; Jamison PM; Jemal A; Wu XC; Friedman C; Harlan L; Warren J; Anderson RN; Pickle LW
J Natl Cancer Inst; 2005 Oct; 97(19):1407-27. PubMed ID: 16204691
[TBL] [Abstract][Full Text] [Related]
15. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
16. PSA testing in Austria: induced morbidity and saved mortality.
Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
[TBL] [Abstract][Full Text] [Related]
17. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
18. [Cancer of the prostate in France: results of the survey CCAFU-FRANCIM].
Soulié M; Villers A; Grosclaude P; Menegoz F; Schaffer P; Mace-Lesec'h J; Sauvage-Machelard M; Molinier L; Grand A
Prog Urol; 2001 Jun; 11(3):478-85. PubMed ID: 11512461
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
